Search Contact
Clinical trials
DISCOVER OUR
CLINICAL RESEARCH

Our Research and Development department is deeply involved in the two-way connection between preclinical and clinical research.

Following you can find our ongoing clinical trials sorted by therapeutic area:

Gastro-intestinal health research

  1. Development of combined nutritional therapies (P. acidilactici CECT 7483 (KABP™-021), L. plantarum CECT 7484 (KABP™-022) and CECT 7485 (KABP™-023) plus prebiotics) for the treatment of Ulcerative Colitis by increasing biodiversity in the microbiota.
  2. Interventional post-marketing study to evaluate i3.1 (P. acidilactici CECT 7483 (KABP™-021), L. plantarum CECT 7484 (KABP™-022) and CECT 7485 (KABP™-023) plus fibers) efficacy on SIBO (Small Intestinal Bacterial Overgrowth) reduction in IBS (Irritable bowel syndrom) patients.

Cardiometabolic research

  1. Comparative study to evaluate the effect of AB-LIFE® (L. plantarum CECT 7527 (KABP™-011), CECT 7528 (KABP™-012) and CECT 7529 (KABP™-013)) in ameliorating simvastatin treatment in hypercholesterolemic patients.
  2. Evaluation of the practical efficacy and safety of AB-LIFE® (L. plantarum CECT 7527 (KABP™-011), CECT 7528 (KABP™-012) and CECT 7529 (KABP™-013)) in cholesterol reduction in patients with hypercholesterolemia.
  3. A trial to evaluate the efficacy of AB-LIFE probiotics product (L. plantarum CECT 7527 (KABP™-011), CECT 7528 (KABP™-012) and CECT 7529 (KABP™-013)) on serum LDL-cholesterol reduction in borderline hyper-LDL-cholesterolemia.
  4. Study to evaluate the impact of Fat-Binder DAMM on Cardio vascular risk prevention.
  5. Study to evaluate the effect of the regular intake of Fat-Binder DAMM on rebound effect in body weight 9 months after a hypocaloric diet period.

Pediatrics research

  1. Prospective study to determine the factors influencing on baby’s colic evolution in babies receiving probiotics (Pediococcus pentosaceus CECT 8330 (KABP™-041), Bifidobacterium longum CECT 7894 (KABP™-042)).
  2. The efficacy of 3 weeks supplementation with the probiotic formula AB‐Kolicare (Pediococcus pentosaceus CECT 8330 (KABP™-041), Bifidobacterium longum CECT 7894 (KABP™-042)) on infant colic – a randomized, double-blind, placebo-controlled, parallel group study.

Women’s health research

  1. Clinical Study to evaluate the effect of AB-Cyscare (Lactobacillus plantarum CECT 8675 (KABP™-062) and CECT 8677 (KABP™-063)) on recurrent cystitis treatment.
  2. Exploratory study to evaluate the effect of AB-Cyscare (Lactobacillus plantarum CECT 8675 (KABP™-062) and CECT 8677 (KABP™-063)) on pathogen variation in recurrent cystitis.
  3. Clinical study to evaluate the effect of AB-Intimus oral capsules (Lactobacillus plantarum CECT 7504 (KABP™-061)) on vaginal microbiota colonization.

Immunology research

  1. Randomized, double-blind, placebo-controlled study to evaluate the combination of a probiotic (P. acidilactici CECT 7483 (KABP™-021), L. plantarum CECT 7484 (KABP™-022) and CECT 7485 (KABP™-023)) with retroviral treatment (alone or with pre-biotics) VIH-1 + adults harboring less than 500 CD4+ cells/mm3.
  2. A randomized, double-blind, placebo-controlled, parallel study to investigate the effect of AB-IMMUNO (L. plantarum CECT 7315 (KABP™-031) and CECT 7316 (KABP™-032)) on nutrient uptake and digestive health in a healthy elderly population.

Oral health research

  1. Colonization study testing AB-Dentalac (L. brevis CECT 7480 (KABP™-052), L. plantarum CECT 7481 (KABP™-051)) chewing gum.
  2. Randomized, double-blind, placebo-controlled study to evaluate the effect of AB-Dentisani (S. dentisani CECT 7746) in dental caries.
  3. A randomized, double-blind, placebo-controlled clinical trial to evaluate the protective effect on dental caries of AB-Dentisani (S. dentisani CECT 7746) combined with arginine-containing toothpaste.
  4. Interventional study to evaluate periimplantitis status in implants treated with probiotics (P. acidilactici CECT 8904, CECT 8906 and P. pentosaceus CECT 8905).

Gut - Brain axis research

  1. Food supplement interventionLactobacillus plantarum CECT 7485 (KABP-023) and Lactobacillus brevis CECT 7480 (KABP-052) in children diagnosed with ADHD (attention-deficit, hyperactivity-impulsivity) or Autism.
  2. Randomized clinical trial to analize the effect of a probiotic mixture (Lactobacillus plantarum CECT 7485 (KABP-023) and Lactobacillus brevis CECT 7480 (KABP-052)) on stress, cognition, emotional state and quality of life.

Nefrology research

  1. Clinical study to evaluate the effect of a symbiotic treatment AB-CKD (L. plantarum CECT 7528 (KABP™-012), CECT 7529 (KABP™-013) and L. brevis CECT 7480 (KABP™-052)) in patients with Chronic Kidney Disease (CKD) in pre-dialysis on systemic inflammation reduction.

We collaborate with public and private academic or industry research institutions around the globe.

Are you interested in joining our clinical trial research?

We are actively looking for R&D collaborations.

SPONSORED RESEARCH PROJECTS

BRAINMETS

AB-BIOTICS develops the project “BRAINMETS: Nous biomarcadors per detecció precoç de metàstasi cerebral en càncer de mama“, based on a collaboration with researchers from Hospital Clínic de Barcelona-IDIBAPS. The project has received funding from ACCIÓ, with number of file PAT15-1-0018.

MICROBIOTA PROJECT

AB-BIOTICS SA in cooperation with the private foundation CAIXA AIDS Research Institute participates in the project RESEARCH AND DEVELOPMENT OF A NEW THERAPY FOR THE RECONSTRUCTION OF INTESTINAL MICROBIOMY IN HIV + IMMUNODISCORDANT PATIENTS with funding from the Ministry of Science, Research and Universities, through the program RETOS in Collaboration program and whose file is RTC-20016-5113-1.The project has been co-financed by the Euro-European Union, through the European Regional Development Fund (FEDER, Fondo Europeo de Desarrollo Regional-in Spanish).

RIS3CAT PROJECT

AB-BIOTICS S.A. participates in the RIS3CAT project COMRDI15-1-0029: New modulating ingredients of the microbiota applying the omics and big data biotechnology, which has been co-financed by the European Union through the European Regional Development Fund (FEDER, Fondo Europeo de Desarrollo Regional- in Spanish).

GLUTEN PROJECT

AB-BIOTICS S.A. in cooperation with the FUNDACIÓN PARA LA INVESTIGACIÓN BIOMEDICA DEL HOSPITAL UNIVERSITARIO RAMON Y CAJAL participates in the Research project of a microorganism with the capacity to degrade gluten as well as other immunotoxic peptides from other cereals, and its development and clinical validation as a pharmaceutical product for the celiac disease, with funding from the Ministry of Science, Innovation and Universities, through the Challenges in Collaboration Program and whose file number is the RTC-2015-3440-1. The project has been co-financed by the European Union, as it is a Program that is aligned with the following Thematic Objective of the Operational Program: Promoting technological development, innovation and quality research.

 

NUTRITIONAL THERAPIES PROJECT

AB-BIOTICS S.A. coordinates the project Development of combined nutritional therapies for the treatment of ulcerative colitis by increasing the biodiversity of the microbiota, in collaboration with the HOSPITAL UNIVERSITARI HOSPITAL VALL D’HEBRON and the FUNDACIÓN PARA INVESTIGACIÓN BIOMÉDICA HOSPITAL GREGORIO MARAÑON. The project has received funding from the Ministry of Science, Innovation and Universities through the Challenges in Collaboration Program and whose file number is the RTC-2015-3548-1. The project has been co-financed by the European Union, as it is a Program that is aligned with the following Thematic Objective of the Operational Program: Promoting technological development, innovation and quality research.

APSIDE PROJECT

AB-BIOTICS S.A. in cooperation with the BOSCH I GIMPERA FOUNDATION, they are investigating within the framework of the multigenic Predictor project for the prevention of secondary effects induced by antipsychotics – APSIDE, with funding from the Ministry of Science, Innovation and Universities, through the Challenges in Collaboration Program and whose file number is the RTC-2015-3440-1. The project has been co-financed by the European Union, as it is a Program that is aligned with the following Thematic Objective of the Operational Program: Promoting technological development, innovation and quality research.

DENTISANI PROJECT

AB-BIOTICS S.A. in cooperation with the FOUNDATION FOR THE PROMOTION OF HEALTH AND BIOMEDICAL RESEARCH IN THE VALENCIAN COMMUNITY, they have started the research project Development of Streptococcus dentisani as probiotic anticaries, with funding from the Ministry of Science, Innovation and Universities, through the Challenges in Collaboration Program and whose number of file is the RTC-2015-4292-1. The project has been co-financed by the European Union, as it is a Program that is aligned with the following Thematic Objective of the Operational Program: Promoting technological development, innovation and quality research.

FARMACD PROJECT

AB-BIOTICS S.A. participates in the project Development of new technology for the realization of DNA arrays, file IPT-2011-1132-010000, developed in collaboration with the UNIVERSIDAD POLITÉCNICA DE VALENCIA, which is being co-financed by the Ministry of Science, Innovation and Universities, within the Plan National Conference on Scientific Research, Development and Technological Innovation 2008-2011.

ERESPONSE PROJECT

AB-BIOTICS S.A. participates in the project eResponse: Prediction software for response to pharmacological treatments for the eReport platform, file TSI-100700-2014-10, developed jointly with the company ORYZON GENOMICS DIAGNOSTICO SL, which is being co-financed by the Ministry of Industry , Energy and Tourism, within the National Plan for Scientific Research, Development and Technological Innovation 2013-2016.

INTELIGEN PROJECT

AB-BIOTICS S.A. participates in the InteliGEN Suite project: Development of a dynamic pharmacogenetic platform for depression, file TSI-020605-2012-56, developed jointly by the companies ASCIDEA COMPUTATIONAL BIOLOGY SOLUTIONS S.L., STACKOPS TECHNOLOGIES S.L. and PASSWORDBANK TECHNOLOGIES S.L. (currently Mas Movil Telecom 3.0 S.A.), which is being co-financed by the Ministry of Industry, Energy and Tourism, within the National Plan for Scientific Research, Development and Technological Innovation 2008-2011.

Ticker name: ABB:SM